- Home
- WHD vs RARE Comparison
WHD vs RARE Comparison
Compare WHD & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHD
- RARE
- Stock Information
- Founded
- WHD 2011
- RARE 2010
- Country
- WHD United States
- RARE United States
- Employees
- WHD N/A
- RARE N/A
- Industry
- WHD Metal Fabrications
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- WHD Industrials
- RARE Health Care
- Exchange
- WHD Nasdaq
- RARE Nasdaq
- Market Cap
- WHD 2.8B
- RARE 3.3B
- IPO Year
- WHD 2018
- RARE 2014
- Fundamental
- Price
- WHD $45.07
- RARE $37.14
- Analyst Decision
- WHD Hold
- RARE Strong Buy
- Analyst Count
- WHD 6
- RARE 15
- Target Price
- WHD $52.33
- RARE $90.53
- AVG Volume (30 Days)
- WHD 676.7K
- RARE 1.2M
- Earning Date
- WHD 07-30-2025
- RARE 07-31-2025
- Dividend Yield
- WHD 1.15%
- RARE N/A
- EPS Growth
- WHD 11.86
- RARE N/A
- EPS
- WHD 2.83
- RARE N/A
- Revenue
- WHD $1,136,010,000.00
- RARE $590,689,000.00
- Revenue This Year
- WHD $1.08
- RARE $18.94
- Revenue Next Year
- WHD $8.32
- RARE $28.93
- P/E Ratio
- WHD $15.93
- RARE N/A
- Revenue Growth
- WHD N/A
- RARE 33.46
- 52 Week Low
- WHD $33.80
- RARE $29.59
- 52 Week High
- WHD $70.01
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- WHD 55.89
- RARE 52.29
- Support Level
- WHD $45.53
- RARE $36.01
- Resistance Level
- WHD $46.94
- RARE $40.19
- Average True Range (ATR)
- WHD 1.43
- RARE 1.47
- MACD
- WHD -0.02
- RARE 0.06
- Stochastic Oscillator
- WHD 64.36
- RARE 49.92
About WHD Cactus Inc.
Cactus Inc is engaged in the designing, manufacturing, and sale of wellheads and pressure control equipment. Its principal products include Cactus SafeDrill wellhead systems, conventional wellheads, and production valves among others. The company also provides mission-critical field services, including service crews to assist with the installation, maintenance, and safe handling of the wellhead and pressure control equipment, as well as repair services for equipment that it sells or rents. It sells or rents its products principally for onshore unconventional oil and gas wells that are utilized during the drilling, completion (including fracturing), and production. The company has two operating segments; Pressure Control, which generates key revenue and Spoolable Technologies.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.